PP
GYRE icon

Paloma Partners’s Gyre Therapeutics GYRE Stock Holding History

Paloma Partners’s Portfolio GYRE Stock Details GYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-8,520
Closed -$471K – 2078
2019
Q2 		$471K Buy
+8,520
New +$532K 0.01% 1074
2014
Q3 		– Sell
-152
Closed -$541K – 1136
2014
Q2 		$541K Buy
+152
New +$496K 0.02% 547

Other funds holding GYRE

NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
2L
22NW LP Seattle, Washington $146M AUM 29.83% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Paloma Partners's GYRE Position: Q3 2019 in Review

Paloma Partners sold out of Gyre Therapeutics (GYRE) in Q3 2019, closing a stake of 8,520 shares — an estimated $471K sold.

Paloma Partners first reported a position in GYRE in Q2 2014 and held it in 2 quarters. The position peaked at $541K in Q2 2014. 42 funds tracked by Wall St. Rank hold GYRE as of Q3 2019.

  • Paloma Partners reported no remaining Gyre Therapeutics position as of Q3 2019 after selling out during the quarter.
  • Paloma Partners sold 8,520 Gyre Therapeutics shares in Q3 2019, an estimated $471K.
  • Paloma Partners first reported a position in Gyre Therapeutics in Q2 2014 and held it in 2 quarters.
  • Paloma Partners's Gyre Therapeutics position peaked at $541K in Q2 2014.
  • 42 funds tracked by Wall St. Rank held Gyre Therapeutics as of Q3 2019.

Based on Paloma Partners's 13F filing for Q3 2019, filed 14 Nov 2019.